Ulcerative Colitis: Epidemiology Forecast to 2026 – Update

2019-04-30
Price :
Published : Apr-2019
No. of Pages : 64

Ulcerative Colitis: Epidemiology Forecast to 2026 – Update

Summary

Ulcerative colitis (UC) is an inflammatory bowel disease (IBD) characterized by long-lasting inflammation and ulcers (sores) in the lining of the colon. UC is limited to the colon and has less frequent complications.

GlobalData’s epidemiological forecast for the diagnosed incidence, diagnosed prevalence, undiagnosed prevalence, and total prevalence of UC in the 7MM is supported by nationally representative, country-specific studies published in peer-reviewed journals of national healthcare databases and registries. In addition, to improve the comparability of the forecast diagnosed incident and diagnosed prevalent cases of UC across markets, GlobalData epidemiologists used sources that provided uniform diagnostic criteria for these subcategories.

In the 7MM, the diagnosed incident cases of UC are expected to increase from 94,303 cases in 2016 to 108,428 cases in 2026, at an Annual Growth Rate (AGR) of 1.5%. The US will have the highest number of diagnosed incident cases of UC over the forecast period, while Spain will have the lowest. In the 7MM, the diagnosed prevalent cases of UC are expected to increase from 1,737,130 cases in 2016 to 1,867,305 cases in 2026, at an AGR of 0.75%. The US will have the highest number of diagnosed prevalent cases of UC over the forecast period, while Spain will have the lowest.

This Update includes revised severity segmentation section in the report and reorganization of severity segmentations in the model.

Scope

– The Ulcerative Colitis (UC) Epidemiology Forecast Report and Epidemiology Forecast Model provide an overview of the risk factors and global trends of UC in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).
– This report also includes a 10-year epidemiological forecast for the diagnosed incident cases, diagnosed prevalent cases, undiagnosed prevalent cases, and total prevalent cases (both diagnosed and undiagnosed) of UC, segmented by sex and age (starting at ages 0-9 years and ending at ages 80 years and older) in these markets. The diagnosed incident cases are further segmented by stage at diagnosis and severity grading. The diagnosed prevalent cases are further segmented by severity grading. Additionally, autoimmune comorbidities, colectomy due to failure of medical management, and mortality due to complications of UC among the diagnosed prevalent cases of UC are also included in this analysis. Furthermore, the report includes diagnosed incident cases and diagnosed prevalent cases of indeterminate colitis (IC) for both sexes and all ages in the 7MM.
– The Ulcerative Colitis epidemiology forecast report and model were written and developed by Masters- and PhD-level epidemiologists.
– The Epidemiology Forecast Report is in-depth, high quality, transparent, and market-driven, providing expert analysis of disease trends in the 7MM.
– The Epidemiology Forecast Model is easy to navigate, interactive with dashboards, and epidemiology-based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over a 10-year forecast period using reputable sources.

Reasons to buy

– The Ulcerative Colitis (UC) Epidemiology Forecast series will allow you to:
Develop business strategies by understanding the trends shaping and driving the global UC market.
– Quantify patient populations in the global UC market to improve product design, pricing, and launch plans.
– Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for UC therapeutics in each of the markets covered.
Understand magnitude of UC population by severity, stage at diagnosis, comorbidities, and other clinically relevant segmentations.

Filed in: Pharmaceutical
Publisher : GlobalData
More Reports
Title Price Buy Now

B-Cell Non-Hodgkin’s Lymphoma: Epidemiology Forecast to 2027

B-Cell Non-Hodgkin's Lymphoma: Epidemiology Forecast to 2027 Summary Non-Hodgkin's lymphoma (NHL) refers to a group of cancers that develop in the lymphatic system. In NHL, the patient's immune system is affected by the uncontrollable growth of malignant white blood cells, resulting in the body's inability to fight infections and other diseases. NHL accounts for 90% of all malignant lymphomas. NHL is one of the most prevalent hematologic cancers in adults and is more commonly diagnosed in developed countries. B-cell lymphomas are the most common form of NHL diagnosed in developed countries, making up approximately 80-85% of NHL cases in the US. GlobalData epidemiologists used age- and sex-specific diagnosed incidence and prevalence rates to forecast the diagnosed incident and prevalent ......
$3995

Post-Traumatic Stress Disorder: Epidemiology Forecast to 2028

Post-Traumatic Stress Disorder: Epidemiology Forecast to 2028 Summary Post-Traumatic Stress Disorder (PTSD) is a psychiatric disorder that can occur in people who have experienced or witnessed a traumatic event such as a natural disaster, a serious accident, a terrorist act, war/combat, rape, or other violent personal assault (American Psychiatric Association, 2018). PTSD affects as many as one in four people who experience traumatic events, and contributes to marked functional disability, health impairment, and social dysfunction. People with PTSD may relive the event via intrusive memories, flashbacks, and nightmares; avoid anything that reminds them of the trauma; and have anxious feelings they didn't have before (North, Hong and Downs, 2018). GlobalData epidemiologists utilized nati......
$3995

Partnerships, Licensing, Investments and M&A Deals and Trends for April 2019 in Pharmaceuticals

Partnerships, Licensing, Investments and M&A Deals and Trends for April 2019 in Pharmaceuticals Summary GlobalData's "Partnerships, Licensing, Investments and M&A Deals and Trends for April 2019 in Pharmaceuticals", report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in April 2019. The report portrays detailed comparative data on the number of deals and their value in the last six months, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provides......
$1000

Allergic Diseases: Pipeline Offers Novel Approaches to Treat Increasingly Prevalent Conditions, with Strong Presence of Cytokine Mediators Among First-in-Class Products

Allergic Diseases: Pipeline Offers Novel Approaches to Treat Increasingly Prevalent Conditions, with Strong Presence of Cytokine Mediators Among First-in-Class Products Summary An allergy or allergic disease is a condition that arises from an adverse reaction to an exogenous antigen, a substance that invokes an immunological response. These conditions are extremely common. The number of people diagnosed with allergic diseases is rising rapidly on a global scale, which is attributable to factors such as population growth and increased urbanization and pollution. In addition, for a minority of these patients, allergic reactions can be severe, debilitating, or even life-threatening. Despite this high disease burden, treatment options are limited for many conditions and patients often recei......
$6995

Digital Therapeutics and Their Impact on Healthcare

Digital Therapeutics and Their Impact on Healthcare Summary Due to increasing levels in healthcare spending combined with declining R&D returns, digital therapeutics (DTx) represent a new way of treatment in which digital systems are used as regulatory?approved, to treat medical conditions as prescribed therapeutic interventions. There is a growing number of DTx developed on the market today as well as pipeline products in development following internationally-recognized, quality, design and manufacturing standards. DTx will provide a new approach to treatment and disease management in which patients have the possibility to learn more about their conditions and treatment options and this will lead to manage their own health and disease conditions. This report provides an overview of cur......
$7995

Pharmaceutical & Healthcare Quarterly Deals Analysis M&A and Investment Trends – Q1 2019

Pharmaceutical & Healthcare Quarterly Deals Analysis M&A and Investment Trends - Q1 2019 Summary GlobalData's "Pharmaceutical & Healthcare Quarterly Deals Analysis M&A and Investment Trends - Q1 2019", report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in Q1 2019. The report portrays detailed comparative data on the number of deals and their value in the last five quarters, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provides information o......
$1500

CountryFocus: Healthcare, Regulatory and Reimbursement Landscape – Italy

CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - Italy Summary GlobalData, the industry analysis specialist, has released its latest report, "CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - Italy". The report is an essential source of information and analysis on the healthcare, regulatory and reimbursement landscape in Italy. It identifies the key trends in the healthcare market and provides insights into the demographic, regulatory, reimbursement landscape and healthcare infrastructure of Italy. Most importantly, the report provides valuable insights into the trends and segmentation of the pharmaceutical and medical device markets. It is built using data and information sourced from proprietary databases, secondary research, and in-house analysis by ......
$1995

Partnerships, Licensing, Investments and M&A Deals and Trends for 2018 in Pharmaceuticals

Partnerships, Licensing, Investments and M&A Deals and Trends for 2018 in Pharmaceuticals Summary GlobalData's "Partnerships, Licensing, Investments and M&A Deals and Trends for 2018 in Pharmaceuticals", report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in 2018. The report portrays detailed comparative data on the number of deals and their value in the last five years, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provides information on th......
$3500

Diabetic Neuropathic Pain Global Clinical Trials Review, H1, 2019

Diabetic Neuropathic Pain Global Clinical Trials Review, H1, 2019 Summary GlobalData's clinical trial report, "Diabetic Neuropathic Pain Global Clinical Trials Review, H1, 2019" provides an overview of Diabetic Neuropathic Pain clinical trials scenario. This report provides top line data relating to the clinical trials on Diabetic Neuropathic Pain. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - ......
$2500

Ebolavirus Infections (Ebola Hemorrhagic Fever) Global Clinical Trials Review, H1, 2019

Ebolavirus Infections (Ebola Hemorrhagic Fever) Global Clinical Trials Review, H1, 2019 Summary GlobalData's clinical trial report, "Ebolavirus Infections (Ebola Hemorrhagic Fever) Global Clinical Trials Review, H1, 2019" provides an overview of Ebolavirus Infections (Ebola Hemorrhagic Fever) clinical trials scenario. This report provides top line data relating to the clinical trials on Ebolavirus Infections (Ebola Hemorrhagic Fever). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). Gl......
$2500
We use cookies to deliver the best possible experience on our website.
By continuing to use this site, or closing this box, you consent to our use of cookies. To learn more, visit our Privacy Policy